Staar Surgical price target lowered to $50 from $65 at Piper Sandler

Piper Sandler analyst Matt O’Brien lowered the firm’s price target on Staar Surgical to $50 from $65 and keeps a Neutral rating on the shares. While the company’s Q2 ICL revenue and EPS slightly beat consensus, the declining sequential domestic sales and revised downward revenue guidance will likely weigh on the stock, the analyst tells investors. While China continues to be the driver of the story, U.S. growth remains a challenge, the firm says.